These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25103496)

  • 1. Monitoring cancer through the blood.
    Paweletz CP; Jänne PA
    Cancer; 2014 Dec; 120(24):3859-61. PubMed ID: 25103496
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
    Sorensen BS; Wu L; Wei W; Tsai J; Weber B; Nexo E; Meldgaard P
    Cancer; 2014 Dec; 120(24):3896-901. PubMed ID: 25103305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
    Kuang Y; Rogers A; Yeap BY; Wang L; Makrigiorgos M; Vetrand K; Thiede S; Distel RJ; Jänne PA
    Clin Cancer Res; 2009 Apr; 15(8):2630-6. PubMed ID: 19351754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib for the treatment of non-small-cell lung cancer.
    Boysen M; Longson C; Stevens A
    Lancet Oncol; 2009 Jan; 10(1):15-6. PubMed ID: 19115513
    [No Abstract]   [Full Text] [Related]  

  • 5. Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
    Lim JU; Woo IS; Jung YH; Byeon JH; Park CK; Kim TJ; Kim HR
    Korean J Intern Med; 2014 Nov; 29(6):830-3. PubMed ID: 25378985
    [No Abstract]   [Full Text] [Related]  

  • 6. VeriStrat validated in patients with non-small-cell lung cancer.
    Butts CA
    Lancet Oncol; 2014 Jun; 15(7):671-2. PubMed ID: 24831978
    [No Abstract]   [Full Text] [Related]  

  • 7. Erlotinib in lung cancer.
    Takano T; Ohe Y
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240472
    [No Abstract]   [Full Text] [Related]  

  • 8. Erlotinib in lung cancer.
    Pao W; Ladanyi M; Miller VA;
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240471
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
    Costa DB; Schumer ST; Tenen DG; Kobayashi S
    J Clin Oncol; 2008 Mar; 26(7):1182-4; author reply 1184-6. PubMed ID: 18309959
    [No Abstract]   [Full Text] [Related]  

  • 10. NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer.
    Rinaldi F; George E; Clark P
    Lancet Oncol; 2011 Aug; 12(8):728-30. PubMed ID: 21928488
    [No Abstract]   [Full Text] [Related]  

  • 11. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
    Wong AS; Seto KY; Chin TM; Soo RA
    J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
    [No Abstract]   [Full Text] [Related]  

  • 12. KRAS wild-type lung cancer: a moving target in an era of genotype migration.
    Oxnard GR; Jänne PA
    J Clin Oncol; 2012 Sep; 30(27):3322-4. PubMed ID: 22869875
    [No Abstract]   [Full Text] [Related]  

  • 13. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
    He J; Tan W; Tang X; Ma J
    Pathol Oncol Res; 2017 Apr; 23(2):307-315. PubMed ID: 27511219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of non-small cell lung cancer: focus on erlotinib. Foreword.
    Cappuzzo F
    Drugs; 2012 Jun; 72 Suppl 1():1-2. PubMed ID: 22712791
    [No Abstract]   [Full Text] [Related]  

  • 15. Erlotinib or gefitinib for non-small-cell lung cancer.
    Kaye FJ; Jantz MA; Dallas J
    N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675909
    [No Abstract]   [Full Text] [Related]  

  • 16. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
    Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
    Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
    Paz-Ares L
    Lancet Oncol; 2012 Mar; 13(3):225-7. PubMed ID: 22277836
    [No Abstract]   [Full Text] [Related]  

  • 18. Erlotinib in lung cancer.
    Nabhan C; Bitran JD
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16236747
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison is beyond IPASS and OPTIMAL.
    Lam KC; Mok TS
    Hong Kong Med J; 2014 Jun; 20(3):176-7. PubMed ID: 24914076
    [No Abstract]   [Full Text] [Related]  

  • 20. Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
    Shrimali RK; Correa PD; Rizwanullah M
    BMJ Case Rep; 2008; 2008():bcr0620080075. PubMed ID: 21716815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.